Who is sponsoring NCT04393220?

NCT04393220 is sponsored by Fuda Cancer Hospital, Guangzhou.

What drugs are being tested in NCT04393220?

Interventions in NCT04393220: Bevacizumab Injection, Nivolumab.

What condition does NCT04393220 study?

NCT04393220 studies Progress Free Survival (PFS) and Overall Survival (OS).

Is NCT04393220 still recruiting?

NCT04393220 is currently completed. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT04393220

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

Completed Phase 2 Last updated 5 September 2021

What this trial tests

Phase 2 trial testing Bevacizumab Injection in Progress Free Survival (PFS) and Overall Survival (OS) in 60 participants. Completed in 31 August 2021.

Timeline

11 May 2020

Primary endpoint
30 July 2021

31 August 2021

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	11 May 2020
Primary completion	30 July 2021
Estimated completion	31 August 2021
Sites	1 location across China

Drugs / interventions tested

Bevacizumab Injection — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Progress Free Survival (PFS) and Overall Survival (OS) — all drugs for Progress Free Survival (PFS) and Overall Survival (OS) →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 18 to 70, any sex, with Progress Free Survival (PFS) and Overall Survival (OS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z, Liu X, Liang J, Liu Y, et al · · 2021 · cited 109× · PMID 34675942 · DOI 10.3389/fimmu.2021.765101
Advances of Targeted Therapy for Hepatocellular Carcinoma.
Niu M, Yi M, Li N, Wu K, et al · · 2021 · cited 39× · PMID 34381735 · DOI 10.3389/fonc.2021.719896
Immunotherapy in Hepatocellular Carcinoma.
Fulgenzi CAM, Talbot T, Murray SM, Silletta M, et al · · 2021 · cited 29× · PMID 34424422 · DOI 10.1007/s11864-021-00886-5
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview.
van Doorn DJ, Takkenberg RB, Klümpen HJ. · · 2020 · cited 18× · PMID 33374927 · DOI 10.3390/ph14010003
Emerging treatment modalities for systemic therapy in hepatocellular carcinoma.
Qing X, Xu W, Zong J, Du X, et al · · 2021 · cited 17× · PMID 34419152 · DOI 10.1186/s40364-021-00319-3
Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.
Liu ZL, Liu JH, Staiculescu D, Chen J. · · 2021 · cited 17× · PMID 34104226 · DOI 10.1177/17588359211018026
Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Tovoli F, De Lorenzo S, Trevisani F. · · 2020 · cited 17× · PMID 33023131 · DOI 10.3390/vaccines8040578

Verify or expand the search:

Other trials of Bevacizumab Injection

Trials testing the same drug.

NCT07111546 — A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] · Phase 2 · recruiting
NCT07089719 — Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study) · Phase 2 · not yet recruiting
NCT06783647 — A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] · Phase 2 · recruiting
NCT06703177 — A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors · Phase 1, PHASE2 · recruiting
NCT03698162 — Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases · NA · terminated

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
NCT03973021 — Very Small Embryonic-like Stem Cells for Erectile Dysfunction · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04393220 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04393220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing